Swiss drugmaker Roche Holding (ROG.VX) expects sales from its diagnostic division to grow faster in the United States than the market trend and it will not reduce prices despite reimbursement cuts in the U.S. health programme, an executive said. In April, the U.S. released final reimbursement rates for 2015 Medicare Advantage plans, which insurers and Wall Street analysts say represents a cut of about 3 percent. "Reimbursement will continue to come under pressure as all healthcare funding comes under pressure," Roland Diggelmann, chief operating officer of Roche Diagnostics Global, told Reuters in Dubai. Roche's diagnostics business had sales worth 10.5 billion Swiss francs ($11.72 billion) last year, a quarter of which came from North America.
via Business News - Yahoo Finance http://ift.tt/1ouGreW
0 commentaires:
Enregistrer un commentaire